Through the deal, Brainlab will be the authorized distributor of Elekta’s Leksell Vantage stereotactic system which won CE Mark approval in the European Union this year. The system also has FDA 510(k) clearance and is commercially available in the US.
Stereotactic neurosurgery is a minimally invasive approach to brain surgery designed to treat specific regions of the brain and spare surrounding healthy tissue, and is often used to implant deep brain stimulation leads or to perform lesioning of small brain targets for treating functional disorders.
“Early adopters of the Vantage system are experiencing clinical and patient benefits from its multiple design innovations. These include stereotactic magnetic resonance imaging with fewer restrictions, easier target coordinate setting during surgery as well as improved anesthetic capabilities,” Elekta neuro portfolio VP Jesper Söderqvist said in a prepared statement.
“We strive to make medical technology more impactful and accessible to physicians and their patients. By partnering with Elekta, we are increasing our reach and providing clinicians with advanced and innovative technology on the stereotactic neurosurgery market,” Brainlab functional & stereotactic neurosurgery VP Paolo Jelmoni said in a prepared release.
The deal expands on an earlier distro deal the two companies signed in June that covered distribution in the European Union.
“Brainlab shares our vision for improving care and outcomes for patients undergoing neurosurgical procedures. The expanded partnership with Brainlab, with a large and specialized sales and service team, to distribute Vantage in the United States gives us a strong position from which to realize the potential of the system to advance the care of patients undergoing stereotactic neurosurgery procedures,” Elekta NA exec VP Peter Gaccione said in a press release.
In November, Elekta said it delayed the rollout of its Unity device, designed to combine magnetic resonance imaging with a linear accelerator for radiation therapy, saying it needed more time to finalize and validate the linac control system.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.